LEADER 03307nam 2200613 a 450 001 9910437996003321 005 20200520144314.0 010 $a1-283-93413-2 010 $a1-4614-5456-5 024 7 $a10.1007/978-1-4614-5456-4 035 $a(CKB)2670000000316161 035 $a(EBL)1081925 035 $a(OCoLC)823388516 035 $a(SSID)ssj0000878460 035 $a(PQKBManifestationID)11560734 035 $a(PQKBTitleCode)TC0000878460 035 $a(PQKBWorkID)10815014 035 $a(PQKB)10546703 035 $a(DE-He213)978-1-4614-5456-4 035 $a(MiAaPQ)EBC1081925 035 $a(PPN)168303086 035 $a(EXLCZ)992670000000316161 100 $a20121227d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAntibody-drug conjugates and immunotoxins $efrom pre-clinical development to therapeutic applications /$fGail Lewis Phillips, editor 205 $a1st ed. 2013. 210 $aNew York $cHumana Press$d2013 215 $a1 online resource (369 p.) 225 0$aCancer drug discovery and development 300 $aDescription based upon print version of record. 311 $a1-4899-9700-8 311 $a1-4614-5455-7 320 $aIncludes bibliographical references and index. 327 $apt. I. Introduction and development perspectives -- pt. II. Development of antibody-drug conjugates -- pt. III. Selection of cytotoxic agents -- pt. IV. Antibody-drug conjugates for hematologic malignancies -- pt. V. Antibody-drug conjugates for solid tumors -- pt. VI. Metabolism -- pt. VII. Immunotoxins. 330 $aThe concept of delivering ?magic bullets? to treat diseases was first proposed by Paul Erlich in the early 1900?s.  The realization of this concept for the treatment of cancer occurred in the late 1990?s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.  ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer. 410 0$aCancer Drug Discovery and Development,$x2196-9906 606 $aAntibody-drug conjugates 606 $aAntibody-toxin conjugates 615 0$aAntibody-drug conjugates. 615 0$aAntibody-toxin conjugates. 676 $a615.37 676 $a615.373 701 $aPhillips$b Gail Lewis$01762253 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437996003321 996 $aAntibody-drug conjugates and immunotoxins$94202046 997 $aUNINA